Glycosylation and the activation of proteinase-activated receptor 2 (PAR2) by human mast cell tryptase

被引:92
作者
Compton, SJ [1 ]
Renaux, B
Wijesuriya, SJ
Hollenberg, MD
机构
[1] Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Diabet & Endocrine Res Grp, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Fac Med, Dept Med, Calgary, AB T2N 4N1, Canada
关键词
tryptase; PAR2; glycosylation;
D O I
10.1038/sj.bjp.0704303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Human mast cell tryptase appears to display considerable variation in activating proteinase-activated receptor 2 (PAR(2)). We found tryptase to be an inefficient activator of wild-type rat-PAR(2) (wt-rPAR(2)) and therefore decided to explore the factors that may influence tryptase activation of PAR(2). 2 Using a 20 mer peptide (P20) corresponding to the cleavage/activation sequence of wt-rPAR2, tryptase was as efficient as trypsin in releasing the receptor-activating sequence (SLIGRL...). However, in the presence of either human-PAR(2) or wt-r PAR(2) expressing cells, tryptase could only activate PAR(2) by releasing SLIGRL from the P20 peptide, suggesting that PAR(2) expressed on the cells was protected from tryptase activation. 3 Three approaches were employed to test the hypothesis that PAR, receptor glycosylation restricts tryptase activation. (a) pretreatment of wt-rPAR(2) expressing cells or human embryonic kidney cells (HEK293) with vibrio cholerae neuraminidase to remove oligosaccharide sialic acid, unmasked tryptase-mediated PAR(2) activation. (b) Inhibiting receptor glycosylation in HEK293 cells with tunicamycin enabled tryptase-mediated PAR(2) activation. (c) Wt-rPAR(2) devoid of the N-terminal glycosylation sequon (PAR(2)T25(-)), but not rPAR(2) devoid of the glycosylation sequon located on extracellular loop-2 (PAR(2)T224A), was selectively and substantially (> 30 fold) more sensitive to tryptase compared with the wt-rPAR(2). 4 Immunocytochemistry using antisera that specifically recognized the N-terminal precleavage sequence of PAR(2) demonstrated that tryptase released the precleavage domain from PAR(2)T25(-) but not from wt-rPAR(2). 5 Heparin : tryptase molar ratios of greater than 2: 1 abrogated tryptase activation of PAR(2)T25(-). 6 Our results indicate that glycosylation of PAR(2) and heparin-inhibition of PAR(2) activation by tryptase could provide novel mechanisms for regulating receptor activation by tryptase and possibly other proteases.
引用
收藏
页码:705 / 718
页数:14
相关论文
共 46 条
  • [1] Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753
  • [2] Extrapancreatic trypsin-2 cleaves proteinase-activated receptor-2
    Alm, AK
    Gagnemo-Persson, R
    Sorsa, T
    Sundelin, J
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 275 (01) : 77 - 83
  • [3] Bohm SK, 1996, BIOCHEM J, V314, P1009
  • [4] TRYPTASE, THE DOMINANT SECRETORY GRANULAR PROTEIN IN HUMAN MAST-CELLS, IS A POTENT MITOGEN FOR CULTURED DOG TRACHEAL SMOOTH-MUSCLE CELLS
    BROWN, JK
    TYLER, CL
    JONES, CA
    RUOSS, SJ
    HARTMANN, T
    CAUGHEY, GH
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1995, 13 (02) : 227 - 236
  • [5] Mast cell tryptase stimulates the synthesis of type I collagen in human lung fibroblasts
    Cairns, JA
    Walls, AF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) : 1313 - 1321
  • [6] Cairns JA, 1996, J IMMUNOL, V156, P275
  • [7] A polymorphic protease-activated receptor 2 (PAR2) displaying reduced sensitivity to trypsin and differential responses to PAR agonists
    Compton, SJ
    Cairns, JA
    Palmer, KJ
    Al-Ani, B
    Hollenberg, MD
    Walls, AF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) : 39207 - 39212
  • [8] Compton SJ, 1998, J IMMUNOL, V161, P1939
  • [9] COMPTON SJ, 1999, PROG INFLAM RES, P229
  • [10] Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and-2
    Corvera, CU
    Déry, O
    McConalogue, K
    Gamp, P
    Thoma, M
    Al-Ani, B
    Caughey, GH
    Hollenberg, MD
    Bunnett, NW
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1999, 517 (03): : 741 - 756